|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
METOCLOPRAMIDE EFFECTS ON G.I. MOTILITY ARE ANTAGONISED BY THE DRUG
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
FENTANYL ANAESTHESIA IN HIGH DOSES MAY CAUSE SEVERE HYPOTENSION &/OR INCREASED FLUID VOLUME REPLACEMENT WHEN USED IN PATIENTS HAVING NIFEDIPINE & BETABLOCKERS BOTH
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF POSTOPERATIVE RESPIRATORY DEPRESSION OR ENHANCE IT
|
CO-ADMINISTRATION CAN LEAD TO REDUCED EFFECTS OF PEGVISOMANT, SO HIGHER DOSES ARE NEEDED TO ACHIEVE RESULTS
|
MAY CAUSE HYPOTENSION, BRADYCARDIA AND DECREASED CARDIAC OUTPUT
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
OPIOD ANALGESICS IN HIGH DOSE MAY RESULT IN DROP IN HEART RATE AND CARDIAC OUTPUT
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
INDINAVIR MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
INDINAVIR MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
KETAMINE EFFECT IS PROLONGED WITH SUBSEQUENT DELAY IN RECOVERY DUE TO CONCOMITANT USE
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|